Fall Clinical News: Deuruxolitinib Provides Long-lasting Benefit in AA
Deuruxolitinib (Leqselvi, Sun Pharma) shows ongoing and clinically meaningful improvements for up to 68 weeks in scalp hair regrowth among alopecia areata patients, according to pooled long-term results from open-label extension presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. The U.S. Food and Drug Administration approved deuruxolitinib (8mg) tablets for the treatment […]